Advanced search
1 file | 3.81 MB Add to list

Targeting ferroptosis to iron out cancer

(2019) CANCER CELL. 35(6). p.830-849
Author
Organization
Abstract
One of the key challenges in cancer research how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the r. An reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.
Keywords
DEPENDENT CELL-DEATH, BUTHIONINE SULFOXIMINE, TUMOR-SUPPRESSOR, INHIBITS, FERROPTOSIS, GLUTAMATE TOXICITY, THERAPEUTIC TARGET, LIPID-PEROXIDATION, OXIDATIVE STRESS, CYCLE ARREST, GLUTATHIONE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.81 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hassannia, Behrouz, et al. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL, vol. 35, no. 6, 2019, pp. 830–49.
APA
Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019). Targeting ferroptosis to iron out cancer. CANCER CELL, 35(6), 830–849.
Chicago author-date
Hassannia, Behrouz, Peter Vandenabeele, and Tom Vanden Berghe. 2019. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL 35 (6): 830–49.
Chicago author-date (all authors)
Hassannia, Behrouz, Peter Vandenabeele, and Tom Vanden Berghe. 2019. “Targeting Ferroptosis to Iron out Cancer.” CANCER CELL 35 (6): 830–849.
Vancouver
1.
Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. CANCER CELL. 2019;35(6):830–49.
IEEE
[1]
B. Hassannia, P. Vandenabeele, and T. Vanden Berghe, “Targeting ferroptosis to iron out cancer,” CANCER CELL, vol. 35, no. 6, pp. 830–849, 2019.
@article{8622888,
  abstract     = {One of the key challenges in cancer research how to effectively kill cancer cells while leaving the healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the r. An reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. The identification of FDA-approved drugs as ferroptosis inducers creates high expectations for the potential of ferroptosis to be a new promising way to kill therapy-resistant cancers.},
  author       = {Hassannia, Behrouz and Vandenabeele, Peter and Vanden Berghe, Tom},
  issn         = {1535-6108},
  journal      = {CANCER CELL},
  keywords     = {DEPENDENT CELL-DEATH,BUTHIONINE SULFOXIMINE,TUMOR-SUPPRESSOR,INHIBITS,FERROPTOSIS,GLUTAMATE TOXICITY,THERAPEUTIC TARGET,LIPID-PEROXIDATION,OXIDATIVE STRESS,CYCLE ARREST,GLUTATHIONE},
  language     = {eng},
  number       = {6},
  pages        = {830--849},
  title        = {Targeting ferroptosis to iron out cancer},
  url          = {http://dx.doi.org/10.1016/j.ccell.2019.04.002},
  volume       = {35},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: